Metrion Biosciences 2017 review

///Metrion Biosciences 2017 review

Thanks to our Customers: the Metrion Biosciences team would like to thank our customers for placing business with us in 2017. We take great pride in providing a high-quality service to advance early stage drug discovery research for our clients, whether it be integrated drug discovery, new target screening, stand-alone safety profiling and/or translational assay support.

Key Points for 2017: Metrion’s stand-alone CRO sales continued on the upward trajectory seen at the end of H1 2017, with year-end invoiced revenue more than double our audited 2016 figure. FTE-based services continued to deliver high quality support to our clients, with demand for microelectrode array (MEA) and translational services increasing in 2017. A particular highlight of 2017 was being able to announce Metrion’s support for LifeArc’s neuroscience small molecule drug discovery research. This includes target screening and translational assays such as microelectrode array, and CiPA-compliant cardiac safety assays. Once again, thanks to the Metrion team and support staff for their hard work in the lab and continued attention to data quality, analysis and interpretation.

Looking Ahead to 2018: Metrion has a number of important announcements in the pipeline for Q1 2018. Keep an eye on our website, follow us on our LinkedIn or Twitter feeds to be amongst the first to hear the news. You can meet our scientists on our booth at SOT in San Antonio, Texas (11th – 15th March), ICMS in Cambridge, UK (20th – 21st June), and SPS in Washington, DC (30th September – 3rd October). Look on our website near the time of each conference for the booth space, contact details of Metrion attendees and poster numbers.

Read the full overview of Metrion Biosciences 2017 activities here.

Contact us if you would like to discuss any of our services.